Top Featured Companies Dominating the Intravenous Pegloticase Landscape
- Agmen Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BioMarin
- Sarepta Therapeutics
- Benitec Biopharma Inc
- Bioblast Pharma
- PTC Therapeutics
- NS Pharma
- Nobel Pharma Co. Ltd
- Santhera Pharmaceuticals
- Pfizer Inc.
- Fibrinogen
- GSK
Browse Key Market Insights with Data Illustration:
In the News
- Amgen announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date. The nearly 300,000-square-foot facility will employ 400 full-time staff. It also features open workspaces to foster collaboration and has been designed to meet the highest environmental sustainability standards, in support of Amgen's commitment to achieve carbon neutrality for all operations by 2027.
- PTC Therapeutics, Inc. announced an agreement with Royalty Pharma plc. to monetize up to USD 1.5 billion of the Evrysdi royalty stream. Under the agreement, Royalty Pharma acquires additional royalties on Evrysdi for USD 1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to USD 500 million or for Royalty Pharma to acquire half of such retained royalties for up to USD 250 million at a later date. PTC maintains all economics associated with up to USD 250 million in remaining commercial sales milestones associated with Evrysdi global net sales.
